Acid Suppression Therapy Does Not Predispose to Clostridium difficile Infection: The Case of the Potential Bias

Objective An adverse effect of acid-suppression medications on the occurrence of Clostridium difficile infection (CDI) has been a common finding of many, but not all studies. We hypothesized that association between acid-suppression medications and CDI is due to the residual confounding in comparison between patients with infection to those without, predominantly from non-tested and less sick subjects. We aimed to evaluate the effect of acid suppression therapy on incidence of CDI by comparing patients with CDI to two control groups: not tested patients and patients suspected of having CDI, but with a negative test. Methods We conducted a case-control study of adult patients hospitalized in internal medicine department of tertiary teaching hospital between 2005–2010 for at least three days. Controls from each of two groups (negative for CDI and non-tested) were individually matched (1∶1) to cases by primary diagnosis, Charlson comorbidity index, year of hospitalization and gender. Primary outcomes were diagnoses of International Classification of Diseases (ICD-9)–coded CDI occurring 72 hours or more after admission. Results Patients with CDI were similar to controls with a negative test, while controls without CDI testing had lower clinical severity. In multivariable analysis, treatment by acid suppression medications was associated with CDI compared to those who were not tested (OR = 1.88, p-value = 0.032). Conversely, use of acid suppression medications in those who tested negative for the infection was not associated with CDI risk as compared to the cases (OR = 0.66; p = 0.059). Conclusions These findings suggest that the reported epidemiologic associations between use of acid suppression medications and CDI risk may be spurious. The control group choice has an important impact on the results. Clinical differences between the patients with CDI and those not tested and not suspected of having the infection may explain the different conclusions regarding the acid suppression effect on CDI risk.

[1]  Spencer E. Harpe,et al.  Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres. , 2014, The Journal of antimicrobial chemotherapy.

[2]  Ashwin N Ananthakrishnan,et al.  Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections , 2013, The American Journal of Gastroenterology.

[3]  J. Pohl.  Clostridium difficile infection and proton pump inhibitors , 2012, Current opinion in pediatrics.

[4]  R. Cavallazzi,et al.  Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis , 2012, The American Journal of Gastroenterology.

[5]  Mitanshu Shah,et al.  Inappropriate Use of Gastric Acid Suppression Therapy in Hospitalized Patients with Clostridium difficile—Associated Diarrhea: A Ten-Year Retrospective Analysis , 2012, ISRN gastroenterology.

[6]  Kumanan Wilson,et al.  The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. , 2010, Archives of internal medicine.

[7]  M. Howell,et al.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. , 2010, Archives of internal medicine.

[8]  D. Gerding,et al.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.

[9]  F. Friedenberg,et al.  Predictors of serious complications due to Clostridium difficile infection , 2009, Alimentary pharmacology & therapeutics.

[10]  T. Louie,et al.  Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low‐endemicity, non‐outbreak hospital setting , 2009, Alimentary pharmacology & therapeutics.

[11]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[12]  R. Cunningham,et al.  Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea? , 2008, The Journal of hospital infection.

[13]  M. Aseeri,et al.  Gastric Acid Suppression by Proton Pump Inhibitors as a Risk Factor for Clostridium Difficile-Associated Diarrhea in Hospitalized Patients , 2008, The American Journal of Gastroenterology.

[14]  H. Soran,et al.  Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. , 2008, QJM : monthly journal of the Association of Physicians.

[15]  Carlene A. Muto,et al.  Antimicrobial-associated risk factors for Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Musher,et al.  Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[17]  G. Raugi,et al.  Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. Donskey,et al.  Vegetative Clostridium difficile Survives in Room Air on Moist Surfaces and in Gastric Contents with Reduced Acidity: a Potential Mechanism To Explain the Association between Proton Pump Inhibitors and C. difficile-Associated Diarrhea? , 2007, Antimicrobial Agents and Chemotherapy.

[19]  D. Fone,et al.  Proton pump inhibitor therapy is a risk factor for Clostridium difficile‐associated diarrhoea , 2006, Alimentary pharmacology & therapeutics.

[20]  D. Snydman,et al.  Use of Gastric Acid–Suppressive Agents and the Risk of Community-Acquired Clostridium difficile–Associated Disease , 2006 .

[21]  L. Lanthier,et al.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Jon Brazier,et al.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe , 2005, The Lancet.

[23]  C. Kelly,et al.  Underlying Disease Severity as a Major Risk Factor for Nosocomial Clostridium difficile Diarrhea , 2002, Infection Control & Hospital Epidemiology.

[24]  Mark A. Miller,et al.  Morbidity, Mortality, and Healthcare Burden of Nosocomial Clostridium Difficile-Associated Diarrhea in Canadian Hospitals , 2002, Infection Control & Hospital Epidemiology.

[25]  S. Shah,et al.  Gastric acid suppression does not promote clostridial diarrhoea in the elderly. , 2000, QJM : monthly journal of the Association of Physicians.

[26]  G E Bignardi,et al.  Risk factors for Clostridium difficile infection. , 1998, The Journal of hospital infection.

[27]  J. Hughes,et al.  Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. , 1982, The Journal of infectious diseases.

[28]  K. Devault,et al.  Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection , 2012 .

[29]  L. Mcfarland.  Update on the changing epidemiology of Clostridium difficile-associated disease , 2008, Nature Clinical Practice Gastroenterology &Hepatology.

[30]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[31]  P. Tooley,et al.  Food and drugs , 1971 .